Header Unit

Breaking: Turing Pharma Reduces Daraprim Price

Tonight Turing Pharmaceuticals announced price cuts to hospitals up to 50% off list price.

From the press release:

Turing Reduces Cost of Daraprim® (pyrimethamine)

Price cuts of up to 50 Percent for Hospitals, Improving Access & Affordability

“We pledge that no patient needing Daraprim will ever be denied access.”

Zug, Switzerland — November 24, 2015 — Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on developing and commercializing innovative treatments for serious diseases and conditions, today unveiled significant price cuts for hospitals on Daraprim.

“Combined with our robust patient access programs, this is an important step in our commitment to ensure ready access to Daraprim at the lowest possible out-of-pocket cost for both hospitals and patients.” said Nancy Retzlaff Turing’s Chief Commercial Officer. “We pledge that no patient needing Daraprim will ever be denied access.”

Turing will provide:

  • Reductions of up to 50 percent of list price for hospitals, which are the first to treat about 80 percent of patients with toxoplasmosis encephalitis — the most common form of toxoplasmosis in the United States.
  • New, smaller bottles of 30 tablets for hospitals to make it easier to stock Daraprim as well as lower their carrying costs. We plan to make these available in early 2016.
  • Sample starter packages at zero cost to ensure physicians treating patients in the community have free and immediate access to start therapy in emergency situations. We plan to make these available in early 2016.

Read the entire release here.

4 Comments Join the Conversation →

  1. Murray Penner

    What this doesn’t say is that this price cut only helps a small
    slice of patients. While patients may start their course of therapy in the
    hospital, most of them finish the majority of their treatment on an outpatient
    basis. The price of the drug is still the same – it’s just that certain customers will have a discount added to it so patients who switch to outpatient access will have to pay the higher price (and each individual hospital will have to work with Turing to get the discounted price). It also doesn’t take into account that the price is still 2,500% higher than it was before for these discounts. That’s sort of like buying a jacket that originally cost a $100 but the retailer jacked up the price to $1,000 and then put the jacket on a 50% sale for $500. Overarching to all of these concerns that need to be mitigated is that the price is 5,000% higher than it was before Turing took over the drug and THAT is why there are all of these issues. There weren’t access issues before.

  2. Jack Dee

    I hope this dirty Jew hangs himself for being greedy.

  3. Jessica Hurtubise

    Why are you posting here, aren’t you late for a Klan meeting or something?

  4. Roderic Graham

    It is very disheartening to read that they are only offering price cuts, instead of lowering the price for patients all together. He intentionally raised the price on the medication that was already extremely high. The discounted price only occurred after the medication was marked up. This goes to show you that there is more money gained in treating a diseases rather than curing it.

Comments are closed.